Jump Financial LLC Purchases New Holdings in Immunovant, Inc. (NASDAQ:IMVT)

Jump Financial LLC bought a new stake in Immunovant, Inc. (NASDAQ:IMVTFree Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 12,026 shares of the company’s stock, valued at approximately $462,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of IMVT. Swiss National Bank grew its stake in Immunovant by 7.2% in the 1st quarter. Swiss National Bank now owns 95,100 shares of the company’s stock valued at $524,000 after buying an additional 6,400 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Immunovant by 205.6% in the 1st quarter. JPMorgan Chase & Co. now owns 461,582 shares of the company’s stock valued at $2,543,000 after buying an additional 310,520 shares during the last quarter. MetLife Investment Management LLC grew its stake in Immunovant by 423.9% in the 1st quarter. MetLife Investment Management LLC now owns 25,184 shares of the company’s stock valued at $139,000 after buying an additional 20,377 shares during the last quarter. BlackRock Inc. grew its stake in Immunovant by 0.9% in the 1st quarter. BlackRock Inc. now owns 3,353,866 shares of the company’s stock valued at $18,479,000 after buying an additional 28,865 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Immunovant by 148.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 690,965 shares of the company’s stock valued at $3,807,000 after buying an additional 412,997 shares during the last quarter. 42.45% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Immunovant

In related news, CFO Eva Renee Barnett sold 4,055 shares of Immunovant stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $32.78, for a total transaction of $132,922.90. Following the completion of the transaction, the chief financial officer now directly owns 326,865 shares of the company’s stock, valued at approximately $10,714,634.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Immunovant news, insider Julia G. Butchko sold 3,265 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $32.78, for a total value of $107,026.70. Following the completion of the transaction, the insider now directly owns 411,260 shares of the company’s stock, valued at $13,481,102.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Eva Renee Barnett sold 4,055 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $32.78, for a total transaction of $132,922.90. Following the completion of the transaction, the chief financial officer now directly owns 326,865 shares of the company’s stock, valued at $10,714,634.70. The disclosure for this sale can be found here. Insiders sold 35,624 shares of company stock valued at $1,248,375 in the last ninety days. Insiders own 4.80% of the company’s stock.

Immunovant Stock Performance

NASDAQ:IMVT opened at $35.50 on Friday. The company has a 50-day moving average of $40.17 and a 200-day moving average of $32.79. The company has a market capitalization of $5.14 billion, a price-to-earnings ratio of -18.02 and a beta of 0.70. Immunovant, Inc. has a 52 week low of $14.05 and a 52 week high of $45.58.

Immunovant (NASDAQ:IMVTGet Free Report) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.45). Sell-side analysts forecast that Immunovant, Inc. will post -1.83 EPS for the current year.

Analyst Ratings Changes

Several research firms have issued reports on IMVT. Cantor Fitzgerald restated an “overweight” rating on shares of Immunovant in a research report on Friday, January 12th. Bank of America raised their price target on shares of Immunovant from $49.00 to $51.00 and gave the stock a “buy” rating in a research report on Thursday, December 21st. Deutsche Bank Aktiengesellschaft began coverage on shares of Immunovant in a research report on Tuesday, December 12th. They issued a “buy” rating and a $50.00 price target on the stock. Piper Sandler raised their price target on shares of Immunovant from $28.00 to $57.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 24th. Finally, Truist Financial raised their price target on shares of Immunovant from $30.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $46.92.

Check Out Our Latest Research Report on IMVT

Immunovant Company Profile

(Free Report)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.

Featured Stories

Want to see what other hedge funds are holding IMVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunovant, Inc. (NASDAQ:IMVTFree Report).

Institutional Ownership by Quarter for Immunovant (NASDAQ:IMVT)

Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.